VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Growth in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 113,911 shares, an increase of 470.4% from the June 15th total of 19,972 shares. Based on an average daily volume of 157,314 shares, the short-interest ratio is presently 0.7 days. Currently, 4.5% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

VivoSim Labs Price Performance

VIVS traded down $0.07 during trading on Monday, hitting $0.81. 122,148 shares of the stock traded hands, compared to its average volume of 823,294. The firm has a 50-day moving average of $1.19 and a 200 day moving average of $1.63. The firm has a market capitalization of $2.11 million, a P/E ratio of -0.26 and a beta of 1.40. VivoSim Labs has a 12-month low of $0.78 and a 12-month high of $5.30.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent SEC filing. Institutional investors own 8.23% of the company’s stock.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.